FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma

NA Sharif, N Odani-Kawabata, F Lu… - Experimental Eye …, 2023 - Elsevier
Prostaglandin (PG) receptors represent important druggable targets due to the many diverse
actions of PGs in the body. From an ocular perspective, the discovery, development, and …

Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer's Disease: Potential and Challenges

S Jain, R Singh, S Paliwal… - Mini Reviews in Medicinal …, 2023 - ingentaconnect.com
Alzheimer's disease (AD) is the most common form of dementia, having characteristic
clinical features of progressive memory loss and visuospatial, language, and cognitive …

Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent …

NA Sharif - Experimental eye research, 2023 - Elsevier
A multitude of pharmacological compounds have been shown to lower and control
intraocular pressure (IOP) in numerous species of animals and human subjects after topical …

[HTML][HTML] Stable gastric pentadecapeptide BPC 157—Possible novel therapy of glaucoma and other ocular conditions

P Sikiric, A Kokot, T Kralj, M Zlatar, S Masnec, R Lazic… - Pharmaceuticals, 2023 - mdpi.com
Recently, stable gastric pentadecapeptide BPC 157 therapy by activation of collateral
pathways counteracted various occlusion/occlusion-like syndromes, vascular, and …

Gene therapies and gene product-based drug candidates for normalizing and preserving tissue functions in animal models of ocular hypertension and glaucoma

NA Sharif - Molecular Aspects of Medicine, 2023 - Elsevier
More than 76 million people worldwide are afflicted with the neurodegenerative eye
diseases described and grouped together as glaucoma. A common feature amongst the …